Madrigal Pharmaceuticals stock reports 71 percent revenue growth in Q2
Madrigal Pharmaceuticals reported a 71 percent revenue increase in Q2 2026, reaching $364.3 million, driven by the expanding adoption of its drug Rezdiffra, which had over 49,000 patients by June 30, 2026. Despite continued losses, the revenue exceeded analyst estimates, and the company's stock, trading at $499.40, is seen by analysts as having significant upside potential. The company maintains a strong cash position to support its commercial expansion.
Madrigal Pharmaceuticals Stock Price Forecast. Should You Buy MDGL?
StockInvest.us rates Madrigal Pharmaceuticals, Inc. (MDGL) as a Sell Candidate with a technical score of -4.42, a rating unchanged from the previous daily evaluation. The stock has fallen 3.32% since a sell signal on September 25, 2026, and is expected to fall an additional 3.76% over the next three months. The analysis indicates several negative technical signals, including sell signals from moving averages and MACD, suggesting continued weak performance.
Trading Systems Reacting to (MDGL) Volatility
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is showing weak near and mid-term sentiment, potentially pressuring its neutral long-term outlook. AI models have generated three distinct trading strategies: a Long Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Short Strategy, all incorporating risk management. The analysis highlights a 42.3:1 risk-reward short setup targeting 12.2% downside against 0.3% risk.
Return on assets % of Madrigal Pharmaceuticals, Inc. – HAN:YDO1
This article provides financial data for Madrigal Pharmaceuticals, Inc. (HAN:YDO1), specifically focusing on its Return on Assets percentage. The content includes a brief overview of the company's financial performance metric.
Cash flow from financing activities of Madrigal Pharmaceuticals, Inc. – HAN:YDO1
This article displays the cash flow from financing activities for Madrigal Pharmaceuticals, Inc. (HAN:YDO1). The content appears to be a financial data page from TradingView, showing the period, value, and change for this financial metric, with a note indicating the data was "Made by humans."
Under an automatic trading plan, director Paul Friedman proposes to sell shares in Madrigal Pharmaceuticals (MDGL).
Madrigal Pharmaceuticals (MDGL) director Paul Friedman has reported a proposed sale of 50,000 common shares, valued at $25,828,000, with an approximate sale date of September 28, 2026. These shares were acquired through the exercise of stock options and the sale will occur automatically under a Rule 10b5-1 trading plan adopted on August 28, 2026. This SEC filing details the transaction, emphasizing its automatic nature under a pre-planned scheme to avoid insider trading allegations.
How New Headquarters Opening At Madrigal Pharmaceuticals (MDGL) Has Changed Its Investment Story
Madrigal Pharmaceuticals recently opened a new headquarters in Conshohocken, PA, signaling its transformation into a fully integrated biopharmaceutical company with over 1,000 employees. While this move highlights increased operating scale and complexity, the core investment story remains centered on the commercial success of its drug Rezdiffra and pipeline development. Investors need to assess if the larger footprint can translate into sustained revenue and disciplined execution, especially with financial projections pointing to profitability by 2029.
Madrigal Pharmaceuticals Price Target Announced at $704.00/Share by Goldman Sachs
Goldman Sachs has set a price target of $704.00 per share for Madrigal Pharmaceuticals. This valuation suggests a significant future potential for the company's stock, according to the investment bank's analysis.
Goldman Sachs assumes Madrigal Pharmaceuticals stock with buy rating
Goldman Sachs initiated coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy rating and a price target of $704.00, noting the company's lead drug, Rezdiffra, has achieved a significant revenue run rate. Madrigal is expanding its pipeline with new licensed assets and reported strong Q2 2026 revenue for Rezdiffra, though it faces challenges with profitability and rising expenses. Other analysts like Wolfe Research, H.C. Wainwright, and Barclays have also provided positive ratings and price targets, reflecting varied perspectives on the company's financial and operational dynamics.
Goldman Sachs assumes Madrigal Pharmaceuticals stock with buy rating By Investing.com
Goldman Sachs has initiated coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy rating and a $704.00 price target, noting the stock is currently undervalued. The company, focused on metabolic dysfunction-associated steatohepatitis (MASH), has achieved a $1.3 billion revenue run rate for its drug Rezdiffra and boasts 91% gross profit margins. Madrigal is also expanding its pipeline with new assets and ongoing trials, despite recent wider net losses and rising expenses.
Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target
Citigroup has initiated coverage of Madrigal Pharmaceuticals (MDGL) with a Buy rating and a price target of $725. This target is significantly higher than the current average analyst price target for MDGL, which stands at $678.18, also reflecting a consensus Buy rating. The article is truncated, suggesting further details are available with a premium subscription.
Madrigal Pharma CEO William John Sibold disposes of common shares worth $4.16 million
Madrigal Pharmaceuticals President and CEO William John Sibold sold 11,193 common shares between September 9-11, 2026, totaling $4.16 million. The shares were sold at prices ranging from $527.88 to $546.38 each, reducing his holdings to 197,746 shares. This transaction information was generated using AI from an SEC EDGAR filing.
Madrigal Pharmaceuticals (NASDAQ: MDGL) insider plans another stock sale after recent multimillion-dollar trades
William Sibold, CEO of Madrigal Pharmaceuticals (MDGL), has filed a Form 144 indicating plans to sell 5,221 shares of common stock, valued at over $2.78 million, through Morgan Stanley Smith Barney LLC. This upcoming sale follows previous transactions in July and September 2026, totaling over $4.7 million, all executed under a pre-arranged Rule 10b5-1 trading plan adopted in June 2026. The shares are related to Restricted Stock Units acquired in September 2025.
Madrigal Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell
Madrigal Pharmaceuticals, Inc. celebrated 10 years as a public company by ringing the Nasdaq Stock Market Closing Bell. Bill Sibold, Chief Executive Officer of Madrigal, led the ceremony at the Nasdaq MarketSite in Times Square. Madrigal Pharmaceuticals is a biopharmaceutical company specializing in novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).
Madrigal Pharmaceuticals (NASDAQ: MDGL) exec plans $3.4M stock sale for tax withholding
Madrigal Pharmaceuticals CEO William John Sibold plans to sell 6,362 shares of common stock, valued at approximately $3.4 million, through Morgan Stanley Smith Barney LLC. This sale is not discretionary but is an automatic transaction to cover tax withholding obligations associated with vested Restricted Stock Units. A prior sale of 2,500 shares for similar reasons occurred on July 20, 2026.
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
Institutional investors are significantly invested in Madrigal Pharmaceuticals (MDGL), owning over 95% of its float, despite a recent stock dip. The company's drug Rezdiffra, the first FDA-approved treatment for MASH, is seeing rising sales even with competition from Novo Nordisk's Wegovy, as the MASH patient population is projected to grow substantially. Madrigal is also viewed as a strong takeover candidate due to Rezdiffra's patent protection, solid cash reserves, and a growing biotech M&A landscape.
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced its participation in the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 1:00 P.M. EDT. The company, focused on therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), will webcast its presentation live. Madrigal's medication, Rezdiffra, is the first approved treatment for MASH with moderate to advanced fibrosis.
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
Madrigal Pharmaceuticals, Inc. announced its participation in the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 1:00 P.M. EDT. The biopharmaceutical company, focused on treating metabolic dysfunction-associated steatohepatitis (MASH) with its approved medication Rezdiffra, will webcast its presentation live. A replay will be available following the event.
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
Madrigal Pharmaceuticals, Inc. announced its participation in the 2026 Cantor Global Healthcare Conference on September 10, 2026, at 1:00 P.M. EDT. The company, focused on MASH therapeutics, will webcast the presentation live, with a replay available afterward. Madrigal Pharmaceuticals is known for Rezdiffra, the first FDA and European Commission-approved medication for MASH with moderate to advanced fibrosis.
When Will Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Become Profitable?
This article analyzes Madrigal Pharmaceuticals, Inc.'s path to profitability. It will likely delve into financial forecasts, analyst expectations, and key milestones that could impact the company's future financial performance and when it might achieve profitability.
Madrigal (NASDAQ: MDGL) officer plans $337K sell-to-cover trade
An officer at Madrigal Pharmaceuticals, Inc. (MDGL), Shannon Kelley, plans to sell 664 shares of common stock valued at $337,019.84. This "sell-to-cover" transaction is intended to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on August 17, 2026, and is not a discretionary sale. The transaction was disclosed via a Rule 144 notice filed on August 20, 2026.
How Investors May Respond To Madrigal (MDGL) Adding J&J R&D Leader John C. Reed To Its Board
Madrigal Pharmaceuticals appointed John C. Reed, Johnson & Johnson's Executive Vice President of Innovative Medicine R&D, to its Board of Directors, signaling a strong emphasis on scientific rigor and late-stage development expertise. This addition, while enhancing the company's scientific narrative, doesn't immediately change the investment focus on Rezdiffra's performance and potential payer pushback. Investors are encouraged to examine Madrigal's full financial report and various fair value estimates to form their own investment verdicts.
Madrigal Pharmaceuticals' General Counsel Executes Automatic Sale of 664 Shares to Cover Tax Withholding
Shannon T. Kelley, General Counsel of Madrigal Pharmaceuticals (NASDAQ:MDGL), automatically sold 664 shares of common stock on August 17, 2026. This sale, priced at $514.97 per share, was executed by the issuer to cover tax withholding obligations related to the vesting of restricted stock units. Following the transaction, Kelley directly retains 11,474 shares of the company's common stock.
Shannon Kelley Sells 664 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock
Shannon Kelley, General Counsel for Madrigal Pharmaceuticals, sold 664 shares of MDGL stock for approximately $341,940 to cover tax obligations related to equity awards. This sale reduced Kelley's stake by 5.47% to 11,474 shares. Despite a 3.9% drop in share price, Madrigal Pharmaceuticals reported better-than-expected quarterly revenue of $364.25 million and an adjusted loss of $1.99 per share, maintaining a "Moderate Buy" consensus rating from analysts.
Madrigal (NASDAQ: MDGL) GC has 664 shares sold for RSU taxes
Madrigal Pharmaceuticals' General Counsel, Kelley T. Shannon, had 664 shares of common stock sold at $514.97 per share on August 17, 2026. This sale was automatically executed by the issuer to cover tax withholding obligations associated with the vesting of restricted stock units. Following this transaction, Shannon directly holds 11,474 MDGL common shares.
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow
Madrigal Pharmaceuticals (MDGL) stock appears undervalued based on its Price/Sales (P/S) ratio, trading below industry and peer averages, suggesting its current price doesn't fully reflect its revenue base. Despite a strong multi-year run and recent pullback, the company passes 5 out of 6 valuation checks, yet its ability to convert pipeline into durable cash flows remains a key risk. Investors focusing on sales-based valuation might see an opportunity, but the long-term justification depends on successful execution and funding.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals announced the grant of equity inducement awards to 13 new non-executive employees on August 15, 2026. These awards, totaling 4,676 time-based restricted stock units, were approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4) to induce employment. The restricted stock units will vest in four equal annual installments, subject to continued employment.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. announced grants of equity inducement awards to 13 new non-executive employees on August 15, 2026, under its 2025 Inducement Plan. These awards, totaling 4,676 time-based restricted stock units, were approved by the independent Compensation Committee and vest over four years, subject to continued employment. This action aligns with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for employment.
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow
Madrigal Pharmaceuticals (MDGL) stock appears undervalued based on sales, trading at a P/S ratio of 9.4x compared to an industry average of 11.1x and a fair estimate of 15.0x. Despite a significant 5.4x gain over five years, a recent pullback has prompted a re-evaluation of its attractiveness. While sales valuation looks promising, the key risk lies in the company's ability to convert revenue into durable cash flows, which will justify a higher multiple.
Madrigal (NASDAQ: MDGL) awards Reed 647 RSUs and options on 1,078 shares
Madrigal Pharmaceuticals (NASDAQ: MDGL) director John C. Reed was granted 647 restricted stock units (RSUs) and options on 1,078 shares. The RSUs will vest 50% on August 15, 2027, and 50% on August 15, 2028, while the stock options, with an exercise price of $507.56 per share, will vest 50% on August 15, 2027, followed by 12.5% quarterly for four periods, all contingent on his continued service. This insider transaction reflects compensation awards, as detailed in a Form 4 SEC filing.
2,410 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by State of Wyoming
The State of Wyoming recently acquired 2,410 shares of Madrigal Pharmaceuticals (MDGL) worth approximately $1.29 million, with institutions collectively owning 98.5% of the company. Madrigal Pharmaceuticals reported stronger-than-expected quarterly results, and analysts maintain a "Moderate Buy" rating despite recent insider share sales.
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug
Madrigal Pharmaceuticals (MDGL) is attracting retail investor attention due to newly acquired U.S. patents for its lead liver disease drug, Rezdiffra, and ongoing speculation about a potential acquisition, possibly by Eli Lilly. Rezdiffra is Madrigal's sole marketed product, and the company is actively expanding its pipeline through licensing agreements. Despite a 1% dip in share price on Monday, analysts maintain a strong 'Buy' rating for MDGL with a significant upside potential.
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
Madrigal Pharmaceuticals' drug Rezdiffra achieved a $1.3 billion trailing-12-month revenue run rate in Q2 2026, with revenue up 71% year-over-year and over 49,000 active patients. The company is expanding its MASH pipeline to 10 assets, primarily for combination with Rezdiffra, targeting weight loss, liver-fat reduction, and genetically driven disease. Upcoming Phase 3 data could significantly expand Rezdiffra's market to F4 compensated cirrhosis, potentially doubling its U.S. addressable market, though international sales face reimbursement challenges.
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
Madrigal Pharmaceuticals, Inc. has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed is currently Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson and brings extensive biopharma industry experience from previous executive roles at Sanofi and Roche. His appointment is expected to provide invaluable scientific expertise, strategic leadership, and global R&D insights as Madrigal continues to advance its MASH pipeline following the successful launch of Rezdiffra.
Madrigal Pharmaceuticals, Inc. Announces Appointment of John C. Reed as Board Director
Madrigal Pharmaceuticals, Inc. announced the appointment of John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed is currently Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson and has held executive leadership positions at Sanofi and Roche. He is recognized for his significant contributions to biomedical research, including authoring over 900 scientific publications and holding more than 130 patents.
Dimensional Fund Advisors LP Has $4.46 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
Dimensional Fund Advisors LP significantly reduced its stake in Madrigal Pharmaceuticals (NASDAQ:MDGL) by 55.9% in the first quarter, selling 10,801 shares and retaining 8,520 shares valued at approximately $4.46 million. Despite this reduction, institutional investors and hedge funds collectively own 98.5% of the company's stock. Madrigal Pharmaceuticals reported strong quarterly revenues of $364.25 million, a 71.2% year-over-year increase, and an adjusted loss per share that beat analyst expectations, contributing to a "Moderate Buy" consensus rating among analysts.
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
Madrigal Pharmaceuticals, Inc. announced the appointment of John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed is currently an Executive Vice President at Johnson & Johnson, leading research and development for innovative medicine, and has extensive experience in the biopharmaceutical industry. His appointment is expected to strengthen Madrigal's scientific expertise and leadership as it continues to advance its MASH pipeline, including its medication Rezdiffra.
Madrigal Pharmaceuticals Appoints Dr. John C. Reed to Expanded Board with Detailed Compensation Plan
Madrigal Pharmaceuticals, Inc. has appointed Dr. John C. Reed to its Board of Directors, expanding the board from eight to nine members. Dr. Reed, elected as a Class II director, will serve on the Science and Technology Committee. His compensation package includes an annual cash retainer and an initial equity award, detailed in a recent Form 8-K filing.
Form 8K Madrigal Pharmaceuticals Inc For: 12 August By Investing.com
Madrigal Pharmaceuticals Inc. filed a Form 8K on August 12. The article provides the title of the filing and mentions that it was published by Investing.com, along with the stock symbol MDGL and its current performance.
Madrigal Pharmaceuticals appoints J&J executive to board
Madrigal Pharmaceuticals (NASDAQ:MDGL) has announced the appointment of John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed is currently Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson, overseeing R&D across various therapeutic areas. Madrigal Pharmaceuticals is focused on treating metabolic dysfunction-associated steatohepatitis (MASH) with its FDA and European Commission-approved medication, Rezdiffra.
Madrigal's Board Adds Scientist With More Than 900 Papers
Madrigal Pharmaceuticals (NASDAQ: MDGL) has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed, currently Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson, brings extensive scientific, leadership, and global drug development experience. His expertise is expected to be invaluable as Madrigal advances its MASH pipeline, including Rezdiffra, and reinforces its commitment to scientific excellence and long-term innovation.
Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Royal Bank of Canada
Royal Bank of Canada increased its stake in Madrigal Pharmaceuticals (NASDAQ:MDGL) by 22.5% in the first quarter, bringing its holdings to 12,526 shares valued at approximately $6.6 million. Institutional investors collectively own 98.5% of the company, with other hedge funds also modifying their holdings. Madrigal Pharmaceuticals reported strong quarterly revenue growth of 71.2% year over year and beat analyst estimates for adjusted EPS.
Precision Trading with Madrigal Pharmaceuticals Inc. (MDGL) Risk Zones
The article provides a precision trading analysis for Madrigal Pharmaceuticals Inc. (MDGL), highlighting a positive near-term sentiment within a long-term strength context despite a weak mid-term bias. It outlines distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones for different risk profiles. The analysis also emphasizes an exceptional 47.1:1 risk-reward setup, targeting a 13.6% gain against a 0.3% risk.
What Is Drawing Fresh Attention To Madrigal Pharmaceuticals (MDGL)?
Madrigal Pharmaceuticals recently reported Q2 results showing increased net losses, drawing attention to its financial performance ahead of an upcoming investor conference. Despite recent volatility, the stock has shown strong long-term momentum with a 1-year total shareholder return of 47.45% and a 5-year return exceeding 5x. The company's valuation narrative suggests it is 24.1% undervalued, primarily due to the potential of its drug Rezdiffra and the expanding market for metabolic and liver diseases.
Precision Trading with Madrigal Pharmaceuticals Inc. (MDGL) Risk Zones
This article provides an analysis of Madrigal Pharmaceuticals Inc. (MDGL), highlighting a positive near-term sentiment within a long-term strong context, despite a weak mid-term bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also details support and resistance levels across near-term, mid-term, and long-term horizons, emphasizing an exceptional risk-reward setup.
What Is Drawing Fresh Attention To Madrigal Pharmaceuticals (MDGL)?
Madrigal Pharmaceuticals (MDGL) is gaining attention after reporting increased net losses in its second-quarter results, ahead of an upcoming investor conference. Despite recent volatility and losses, the stock shows strong long-term momentum with a 1-year total shareholder return of 47.45%. The company's valuation narrative suggests it is 24.1% undervalued, primarily due to the potential of its drug Rezdiffra in the growing MASH market, though future studies and pricing remain key swing factors.
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH Expansion
Madrigal Pharmaceuticals reported a wider net loss of US$57.94 million in Q2 2026, up from US$42.28 million a year prior, driven by the costs of scaling its MASH-focused business. Despite the increased losses, the company's stock rose 9.1%, indicating investor focus on the long-term potential of its drug Rezdiffra and its broader MASH toolkit, including a recent siRNA partnership. Analysts project significant revenue and earnings growth for Madrigal by 2029, with a fair value indicating a substantial upside from its current price.
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH Expansion
Madrigal Pharmaceuticals (MDGL) reported a wider Q2 2026 net loss of US$57.94 million, up from US$42.28 million a year prior, largely due to the costs associated with scaling its MASH-focused business. Despite the increased losses, the company's investment narrative still centers on Rezdiffra becoming a standard of care for MASH, with projected revenues of $3.2 billion and earnings of $935.6 million by 2029. Investors are encouraged to consider the implications of these rising expenses on future profitability and the company's valuation.
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH Expansion
Madrigal Pharmaceuticals reported a wider Q2 2026 net loss of US$57.94 million, up from US$42.28 million a year earlier, reflecting the high costs associated with scaling its MASH-focused business. Despite the increased losses, the stock rose 9.1%. The company's investment narrative hinges on Rezdiffra becoming a standard of care for MASH, with projections of $3.2 billion revenue by 2029.
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH Expansion
Madrigal Pharmaceuticals (MDGL) reported a wider net loss of US$57.94 million in Q2 2026, up from US$42.28 million a year earlier, driven by the costs of scaling its MASH-focused business. Despite the increased losses, the article emphasizes that the investment narrative hinges on Rezdiffra becoming a durable standard of care for MASH, with analysts projecting significant revenue and earnings by 2029. The company's efforts to broaden its MASH toolkit beyond Rezdiffra, such as the siRNA partnership, are also noted as potential long-term catalysts.
